Incidence and HR of shingles
| Result | nbDMARD n=3673 | All TNF n=11 881 | Etanercept n=4139 | Infliximab n=3475 | Adalimumab n=4267 |
|---|---|---|---|---|---|
| Follow-up (patient-years) | 5417 | 17 048 | 6122 | 4529 | 6397 |
| Shingles events | 45 | 275 | 99 | 91 | 85 |
| Shingles incidence (/100 patient-years) | 0.8 (0.6–1.1) | 1.6 (1.4–1.8) | 1.6 (1.3–2.0) | 2.0 (1.6–2.5) | 1.3 (1.1–1.6) |
| Shingles unadjusted HR | Ref | 1.9 (1.4–2.6) | 1.7 (1.2–2.5) | 2.4 (1.7–3.4) | 1.7 (1.2–2.5) |
| Shingles adjusted HR* | Ref | 1.7 (1.1–2.7) | 1.7 (1.0–2.7) | 2.2 (1.4–3.4) | 1.5 (0.9–2.4) |
↵* Adjusted rates using propensity modelling described in the Methods section and using multiple imputations to replace missing baseline variables.
nbDMARD, non-biological disease-modifying antirheumatic drug; TNF, tumour necrosis factor.